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1. Introduction  
Breast cancer is one of the most common non-cutaneous type of cancer in women in 
worldwide and a leading cause of cancer-related deaths, and is increasing year by year in 
almost every areas of the globe. Breast cancer is commonly classified into the following two 
major types: (1) non-invasive breast cancer (cancer cells are confined within the duct and 
lobules) and (2) invasive breast cancer (cancer cells invade through the walls of the duct or 
lobules and infiltrate the surrounding tissues). Various kinds of treatments are available for 
breast cancer, such as chemotherapy, radiotherapy and hormone therapy (Ragaz, 2009). 
Many indole derivatives are reported as potent breast cancer agents, such as aplysinopsin 
analogs and indole-3-carbinols. Aplysinopsins are indole-derived marine natural products. 
The parent aplysinopsin was isolated for the first time (Kazlauskas, et al, 1977) as the major 
metabolite of eight Indo-Pacific sponge species, which are representatives of the genus 
Thorecta. The N-1-unsubstituted aplysinopsins have generated considerable interest due to 
their potentially useful medicinal properties (Dobroslawa, et al, 2009). Aplysinopsin has 
been reported as a potent cytotoxic agent against the Kβ-cell line and methyl-aplysinopsins 
against L-1210 and Kβ-cell lines has been reported as potent cytotoxic agents (Hollenbeak & 
Schmitz, 1977), and the anticancer activities of aplysinopsin and methyl-aplysinopsins 
against both 1210- and Kβ-cells has also been reported (Kondo et al. 1994). Indole-3-carbinol, 
a phytochemical derived from cruciferous vegetables such as broccoli and Brussel sprouts, 
exhibits potent antiproliferative effects against human breast cancer cells and has been 
shown to decrease metastatic spread of tumors in experimental animals (Brew, et al., 2010). 
From the above observations and as part of a program for the development of small 
molecules as potential anticancer treatments (Thirupathi Reddy, et al., 2010 and Narsimha 
Reddy et al., 2010), we initiated a drug discovery program to identify novel benzyl-
aplysinopsin analogs as potent breast cancer agents.  
Combretastins are plant products from the South African tree Combretum caffrum. This 
compound was found to inhibit tubulin polymerization, and competitively inhibit the 
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binding of radiolabeled colchicines to tubulin. Investigation of combretastatins revealed that 
combrestastatin A-4 was active against multidrug resistant (MDR) cancer cell lines 
(McGown, et al., 1990; Lin, et al., 1988 and Cushman, et al 1991). Combretastatin (A-4), as 
well as its trans-isomer and a number of related substances, has been found to cause mitotic 
arrest in cells in culture at cytotoxic concentrations. trans-Tetrahydroxystilbene and a 
number of other related substances were also reported to be cytotoxic agents (Lin, et al 
1988). Also, many natural products possessing a trimethoxybenzene ring, e.g., colchicines, 
and podophyllotoxins, were found to be potent cytotoxic agents that exert their antitumor 
property by their antitubulin character. In view of the known antitubulin activity of 
combretstatin, a large number of its derivatives have been synthesized and evaluated for 
antitubulin activity. Some of the structural modifications carried out on these molecules are 
emerging as potent breast cancer agents. These observations encouraged us to also 
investigate combretastatin analogs as potent breast cancer agents.  
Both the naturally occurring stilbene derivatives i.e. resveratrol (trans-3,5,4’-
trihydroxystilbene) and structurally related combretastatin analogs have been reported as 
cytotoxic agents. Resveratrol is one of the phytoalexins widely distributed in plants products 
such as grapes, berries, peanuts, and red wine. Resveratrol has recently been reported as a 
potential chemotherapeutic agent due to its striking inhibitory effects on cellular events 
associated with cancer initiation, promotion, and progression (Jang, et al., 1997). In addition, 
there are several reports on the anti-cancer activity of resveratrol in animal models (Baur, et al., 
2006). Resveratrol interacts with multiple molecular targets in vitro, and exhibits cytotoxic 
effects against breast, skin, gastric, colon, esophageal, prostate, and pancreatic cancer cells, and 
leukemia cells (Baur, et al., 2006). Based on the anticancer activity of resveratrol analogs we 
also focused on the synthesis several resveratrol analogs as potent breast cancer agents.  
2.1 Synthesis and evaluation of in vitro anticancer activity of (Z)-5-((N-benzyl-1H-
indol-3-yl) methylene) imidazolidine-2,4-diones and (Z)-5-((1-benzyl-1H-indol-3-yl) 
methylene)thiazolidine-2,4-diones 
A series of novel substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-
diones and (Z)-5-((1-benzyl-1H-indol-3-yl)methylene)thiazolidine-2,4-diones that incorporate a 
variety of substituents in both the indole and N-benzyl moieties, and that are considered 
structurally related to the natural product, aplysinopsin, were synthesized utilizing aldol 
condensation chemistry under both microwave irradiation and conventional heating 
methodologies (Scheme 1). A library of simple and substituted N-benzylindole-3-
carboxaldehydes were synthesized in 85-90% yield by reacting the corresponding indole-3-
carboxaldehydes with various substituted benzyl halides under phase-transfer catalytic (PTC) 
conditions using triethylbenzyl ammonium chloride (TEBA) and 50% w/v aqueous NaOH 
solution in dichloromethane (Scheme 1). Aldol condensation of the appropriate N-
benzylindole-3-carboxaldehyde with hydantoin or 2-iminothiazolidin-4-one, in the presence of 
CH3COOH and ammonium acetate and utilizing both microwave irradiation and 
conventional heating methods (Scheme 1), afforded a series of novel simple and substituted 
(Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones (3a-s) and (Z)-5-((1-
benzyl-1H-indol-3-yl) methylene) thiazolidine-2,4-diones (4a-i) (Table 1). Microwave 
irradiation using an open vessel in a domestic microwave oven (1100 W; Kenmore) at 
atmospheric pressure afforded product yields in the range of 85–93% in 30–60s. All the 
synthesized compounds were fully characterized by 1H NMR, 13C NMR. The resulting analogs 
were evaluated for their anti-proliferative activity against a panel of human MCF-7, MDA-MB-
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231/ATCC, HS-578T, BT-549, T-47D, MDA-MB-468 breast cancer cell lines (Tables 1-3). 
Compound (Z)-methyl-1-(4-cyanobenzyl)-3-((2,5-dioxoimidazolidin-4-ylidene) methyl)-1H-
indole-6-carboxylate (3n) exhibited GI50 values of 970nM against HS 578T breast cancer cells, 
and afforded GI50 values ranging from 0.97µM-4.1µM against HS 578T, MCF-7, MDA-MB-
231/ATCC, BT-549, T-47D, MDA-MB-468 (Table 3) (Narsimha Reddy et al, 2011). Two other 
analogs, (Z)-5-((1-(2-bromobenzyl)-1H-indol-3-yl)methylene) imidazolidine-2,4-dione (3f) and 
(Z)-5-((1-benzyl-5-methyl-1H-indol-3-yl)methylene) imidazolidine-2,4-dione (3j) exhibited IC50 
values of 4.4µM and 5.2µM against MCF-7 cells (Table 2) (Narsimha Reddy et al, 2011). From 
the series of 2-iminothiazolidin-4-ones the compound (Z)-5-((5-chloro-1-(4-fluorobenzyl)-1H-
indol-3-yl)methylene)-2-iminothiazolidin-4 one (4c) exhibited growth inhibition (GI50= 3.7µM) 
against cultured HS 578T cancer cells (Table 3). 
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Scheme 1. Reagents and conditions: (a) appropriate benzylhalide, aqueous NaOH solution, 
triethylbenzylammonium chloride, DCM, RT; (b) Method A: hydantoin (or), 2-
iminothiazolidin-4 one, ammonium acetate in acetic acid, microwave irradiation, 40-50 
seconds, 87-95% yield; (c) Method-B: hydantoin (or) 2-iminothiazolidin-4 one, ammonium 
acetate in acetic acid, 120-125 0C, 8-12 hours, 74-85% yield. 
 
S. No. R1 R2 R3 X Y 
3a H H H O NH 
3b H H p-CN O NH 
3c H H p-NO2 O NH 
3d H H p-Cl O NH 
3e H H p-COOCH3 O NH 
3f H H o-Br O NH 
3g H H p-F O NH 
3h Cl H H O NH 
3i Br H p-OCH3 O NH 
3j CH3 H H O NH 
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S. No. R1 R2 R3 X Y 
3k Br H H O NH 
3l OCH3 H H O NH 
3m H H p-CH3 O NH 
3n H COOCH3 p-CN O NH 
3o COOCH3 H p-CN O NH 
3p H H p-CN O NH 
3q H H H O NH 
3r H Cl H O NH 
3s H OCH3 H O NH 
4a H H o-F NH S 
4b Cl H o-F NH S 
4c Cl H p-F NH S 
4d Br H o-F NH S 
4e Br H p-F NH S 
4f H COOCH3 p-CN NH S 
4g H COOCH3 p-COOCH3 NH S 
4h COOCH3 H p-CN NH S 
4i COOCH3 H p-COOCH3 NH S 
Table 1. List of N-benzyl aplysinopsin analogs synthesized (3a-s and 4a-i). 
 
Entry 
Breast cancer cell lines 
MCF-7 (IC50) MDA-231 (IC50) 
3a 27.3 15.7 
3b 14.1 17.6 
3c 10.9 23.3 
3d 21.4 25.3 
3e 15.4 18.4 
3f 4.4 21.8 
3g 22.3 32.8 
3h 9.2 18.0 
3i 16.4 23.2 
3j 5.2 20.1 
3k 7.6 12.4 
3l 7.2 7.0 
3m 20.2 22.1 
Table 2. IC50 values for simple and substituted N-benzyl aplysinopsin analogs (3a-m). 
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Breast Cancer Panel/cell line 
3n 4c 
GI50 LC50 GI50 LC50 
MCF7 3.55 >100 >100 >100 
MDA-MB-231/ATCC 3.32 >100 6.45 >100 
HS 578T 0.97 >100 3.67 >100 
BT-549 1.24 >100 98.8 >100 
T-47D 1.50 >100 >100 >100 
MDA-MB-468 4.14 >100 >100 >100 
aGI50: 50% Growth inhibition, concentration of drug resulting in a 50% reduction in net protein increase 
compared with control cells. bLC50: Lethal concentration, concentration of drug lethal to 50% of cells 
Table 3. IC50 values for compounds 3n and 4c. 
2.2 Synthesis and in vitro cytotoxicity evaluation of (Z)-2-amino-5-(1-benzyl-1H-indol-
3-yl) methylene-1-methyl-1H-imidazol-4(5H)-ones 
Another series of substituted (Z)-2-amino-5-(1-benzyl-1H-indol-3-yl)methylene-1-methyl-1H-
imidazol-4(5H)-ones were synthesized (Scheme 2) utilizing similar aldol condensation 
chemistry. Simple and substituted N-benzylindole-3-carboxaldehydes were synthesized in 85-
90% yield by reacting the corresponding indole-3-carboxaldehydes with various substituted 
benzyl halides under phase-transfer catalytic (PTC) conditions using triethylbenzyl 
ammonium chloride (TEBA) and 50% w/v aqueous NaOH solution in dichloromethane. Aldol 
condensation of the appropriate N-benzylindole-3-carboxaldehyde with creatinine, in the 
presence of CH3COOH and sodium acetate and utilizing both microwave irradiation and 
conventional heating methods (Scheme 2), afforded a series of novel simple and substituted 
(Z)-2-amino-5-(1-benzyl-1H-indol-3-yl)methylene-1-methyl-1H-imidazol-4(5H)-ones. 
Evaluation of analogs these analogs for in vitro cytotoxicity activity against MCF-7, MDA-MB-
231/ATCC, HS-578T, BT-549, T-47D, MDA-MB-468 human breast cancer cell lines is shown in 
Table 4 (Narsimha Reddy et al, 2010). From this series, compounds, (Z)-2-amino-5-((1-(2-
bromobenzyl)-1H-indol-3-yl)methylene)-1-methyl-1H-imidazol-4-(5H)-one (5e) and (Z)-
methyl 4-((3-((2-amino-1-methyl-4-oxo-1H-imidazol-5(4H)-ylidene)methyl)-1H-indol-1-
yl)methyl)benzoate (5f) showed good growth inhibition with GI50 values ranging from 1.5µM-
4µM, and LC50 values ranging from 5.7 µM->100 µM (Table 4).  
 
Breast Cancer Panel/ 
cell lines 
Compound 5e 
Molar concentrations
Compound 5f 
Molar concentrations 
GI50 LC50 GI50 LC50 
MCF7 2.45 x10-6 7.78 x10-5 2.25 x10-6 4.81 x10-5 
MDA-MB-231/ATCC 2.01 x10-6 1.43 x10-5 4.07 x10-6 4.67 x10-5 
HS 578T 2.17 x10-6 >1.0 x10-4 3.97 x10-6 >1.00 x10-4 
BT-549 1.73 x10-6 >1.0 x10-4 2.05 x10-6 >1.00 x10-4 
T-47D 1.50 x10-6 5.74 x10-6 1.68 x10-6 1.31 x10-5 
MDA-MB-468 1.63 x10-6 6.78 x10-6 1.69 x10-6 6.90 x10-6 
aGI50: 50% Growth inhibition, concentration of drug resulting in a 50% reduction in net protein increase 
compared with control cells. bLC50: Lethal concentration, concentration of drug lethal to 50% of cells 
Table 4. IC50 values for compounds 3e and 3f. 
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5a R1=R2 = R3= H 5g R1=H, R2=H, R3=p-F  
5b R1=H, R2=H, R3=p-CN  5h R1=Cl, R2=R3=H  
5c R1=H, R2=H, R3=p-NO2  5i R1=Br, R2=H, R3=OCH3  
5d R1=H, R2=H, R3=p-Cl  5j R1=CH3, R2=R3=H  
5e R1=H, R2=H, R3= o-Br 5k R1=Br, R2=R3=H  
5f R1= H, R2=H, R3=p-COOCH3  5l R1=OCH3, R2= R3=H  
5m R1=H, R2=H, R3=p-CH3  
Scheme 2. Synthesis of (Z)-2-amino-5-(1-benzyl-1H-indol-3-yl)methylene-1-methyl-1H-
imidazol-4(5H)-one analogs: Reagents and conditions (a) appropriate benzyl halide, 
aqueous NaOH solution, triethylbenzyl ammonium chloride, DCM, RT; (b) Creatinine (1.1 
mol. eq), NaOAc (1.2 mol. eq), AcOH, MWI, 30-60 sec; (c) Creatinine (1.1 mol. eq), NaOAc 
(1.2 mol. eq), AcOH, reflux, 7-10 h. 
2.3 Synthesis and invitro cytotoxicity evaluation of N-alkyl-3-hydroxy-3-(2-imino-3-
methyl-5-oxo-imidazolidin-4-yl)indolin-2-one 
A third series of N-alkyl-3-hydroxy-3-(2-imino-3-methyl-5-oxo-imidazolidin-4-yl)indolin-2-one 
analogs that incorporated a variety of substituents in both the isatin phenyl and N-benzyl 
moieties were also synthesized. These novel analogs (8a-w) were prepared by condensation of 
the appropriate substituted N-alkyl isatin with creatinine, in the presence of sodium acetate 
and acetic acid via both microwave irradiation and conventional heating methodologies 
(Scheme 3) (Narsimha Reddy et al, 2010). Of these two methods, microwave irradiation was 
found to be advantageous over conventional heating, since the product yields were 83-94% for 
the former method, but only 70-83% for the latter method. In addition, the time course of the 
reaction was very fast using microwave irradiation (20-40 sec) compared to 6-8 h for 
conventional heating. The simple and N-alkyl substituted isatins (6a-j) were all prepared 
utilizing literature methods (Macpherson, et al., 2007; Jacobs, et al., 1948 and Shindikar, et al., 
2006). All the synthesized compounds were characterized by 1H-NMR and 13C-NMR 
spectrometry. The geometry of the hydroxyl position in the representative compounds 8a, 8b 
and 8t was established as trans to the 4′-methyne hydrogen from X-ray crystallographic data 
(Narsimha Reddy et al, 2009). From the X-ray diffraction and 1H-NMR data, analogs 8a-8w 
were mixtures of RR and SS isomers. This is consistent with the mechanism of the aldol 
condensation reaction of 6 with 7, which proceeds via the formation of the E-enolate, as per the 
Zimmerman–Traxler model, which favors anti products, and is predicted to lead to the 
formation of equimolar RR and SS enantiomers. We also determined from the crystal 
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structures of 8a, 8b and 8t that the 3-hydroxy group was trans to the 4′-methyne hydrogen, 
which may explain the inability of these analogs to undergo facile dehydration. The 
cytotoxicity data on these analogs is provided in Table 5 (Narsimha Reddy et al, 2010). Two 
analogs, 3-hydroxy-3-(2-imino-3-methyl-5-oxoimidazolidin-4-yl)-1-(4-methoxy benzyl)indolin-
2-one (8n) and 5-chloro-3-hydroxy-3-(2-imino-3-methyl-5-oxoimidazolidin-4-yl)-1-(4-
methoxybenzyl)indolin-2-one (8o), showed growth inhibition with GI50 values ranging from 
2µM-60µM. Substitution of a methoxy group at the 4th position of N-benzyl group (8n) 
increases the activity over the breast cancer cells. Further the substitution of chloro group at 5th 
position of N-benzyl p-methoxy isatin (8n) increased the activity. 
 
N
a (or) b
O
O
R1
N
O
N
NH
HO
O
NH
CH3+
NH
N
O
NH
CH3
R1
R2 R2
7
R3
6a-j
R3
8 a-w  
Scheme 3. Reagents and conditions: (a) Method A: sodium acetate in acetic acid, microwave 
irradiation, 20-40 seconds, 83-94% yield; (b) Method-B: sodium acetate in acetic acid, 115-120 
0C, 6-8 hours, 70-83% yield. 
 
Compound R1 R2 R3 
8a H H H
8b F H H
8c Cl H H
8d Br H H
8e Br Br H
8f NO2 H H
8g H H -CH3
8h F H -CH3
8i Cl H -CH3
8j Br H -CH3
8k H H -Bz
8l Cl H -Bz
8m Br H -Bz
8n H H 4-OCH3 Bz 
8o Cl H 4-OCH3 Bz 
8p Br H 4-OCH3 Bz 
8q H H 4-Cl Bz
8r H H 4-COOCH3Bz 
8s H H 4-CN Bz 
8t H H -C6H5
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Compound R1 R2 R3 
8u H H -COCH3 
8v Cl H -COCH3 
8w H H -SO2C6H5 
 
Breast Cancer  
Panel/cell lines 
Compound 8o
Molar concentrations
Compound 8n 
Molar concentrations 
GI50 LC50 GI50 LC50 
MCF7 3.22 >100 6.93 >100 
MDA-MB-231/ATCC 8.55 >100 19.4 >100 
HS 578T 2.04 >100 60.3 >100 
BT-549 2.98 54.9 8.45 97.0 
T-47D 13.5 >100 32.0 >100 
MDA-MB-468 2.29 >100 11.6 >100 
aGI50: 50% Growth inhibition, concentration of drug resulting in a 50% reduction in net protein increase 
compared with control cells. bLC50: Lethal concentration, concentration of drug lethal to 50% of cells 
Table 5. IC50 values for compounds 8o and 8n. 
2.4 Synthesis and in vitro cytotoxicity evaluation of benzo[b]thiophene phenyl 
acrylontriles as novel combretastatin analogs 
A series of combretastatin analogs were prepared via the reaction of benzo[b]thiophene-2-
carbaldehyde or benzo[b]thiophene-3-carbaldehyde with simple and substituted benzyl 
cyanides in 5% sodium methoxide methanol (Scheme 4) and evaluated for their in vitro 
cytotoxicity against a panel of human MCF-7, MDA-MB-231/ATCC, HS-578T, BT-549, T-
47D, breast cancer cell lines (Table 6). Two analogs, (Z)-3-(benzo[b]thiophen-3-yl)-2-(3,4-
dimethoxy phenyl)acrylonitrile (11b), and (Z)-3-(benzo[b]thiophen-3-yl)-2-(3,4,5-
trimethoxyphenyl) acrylonitrile (11c) showed very potent growth inhibitory properties 
against four breast cancer cell lines utilized (MCF7, MDA-MB-231/ATCC, HS 578T, BT-549), 
with GI50 values ranging from 28nm-269nm. benzo[b]thiophene-2-carbaldehyde  series of 
compounds (11a-d) generally exhibits greater potency than the benzo[b]thiophene-3-
carbaldehyde series of compounds (13a-d) over all the breast cancer cell lines screened. 
 
Breast Cancer Panel/cell line 
Compound 11b
Molar concentrations 
Compound 11c 
Molar concentrations 
GI50 LC50 GI50 LC50 
MCF7 47.8x10-9 >100.0 40.2 x10-9 >100.0 
MDA-MB-231/ATCC 269 x10-9 >100.0 33.0 x10-9 >100.0 
HS 578T 30.0 x10-9 >100.0 42.7 x10-9 >100.0 
BT-549 28.3 x10-9 >100.0 36.6 x10-9 >100.0 
T-47D >100.0 >100.0 27.2 x10-6 >100.0 
aGI50: 50% Growth inhibition, concentration of drug resulting in a 50% reduction in net protein increase 
compared with control cells. bLC50: Lethal concentration, concentration of drug lethal to 50% of cells 
Table 6. IC50 values for compounds 11b and 11c. 
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Scheme 4. Synthesis of simple and substituted benzo[b]thiophene phenyl acrylontriles (11a-
d and 13a-d). 
2.5 Synthesis and in vitro cytotoxicity evaluation of resveratrol analogs 
A series of novel resveratrol analogs were synthesized (Scheme 5) and evaluated for their 
anti-proliferative activity against MCF-7 and MDA-231 breast cancer cells (Table 7). The 
initial step in the synthesis of resveratrol analogs 16a-i is the synthesis of the common 
intermediate trans-2-formyl-3,4′,5-trimethoxystilbene (15), which was prepared via 
formylation of (E)-1,3-dimethoxy-5-(4-methoxystyryl)benzene (14) with a slight excess of 
phosphorous oxychloride (POCl3) in dimethyl formamide (DMF) at 0 oC in 69% yield (Xian, 
et al, 2007). The novel resveratrol analogs 16a-i were then prepared by aldol condensation of 
resveratrol-2-carboxaldehyde with the appropriate active methylene compound, utilizing a 
variety of reaction conditions, i.e., ammonium acetate in acetic acid under microwave 
irradiation (MWI), by refluxing the reactants in ethanol, or by stirring the reaction at 
ambient temperature in methanol. The synthetic routes to the resveratrol analogs 16a-i are 
illustrated in Scheme 5. Compounds 16a-i were fully characterized by 1H-NMR and 13C-
NMR spectrometry. The geometry of the double bond was established as Z, based on NMR 
spectrometric data. The X-ray crystallographic data of the representative compound 16e 
confirmed the Z-geometry in this analog (Madadi, et al, 2010). The most potent compound, 
(Z)-5-(2,4-dimethoxy-6-(4-methoxystyryl)benzylidene)-2-imino-1-methylimidazolidin-4-one 
(16e), had IC50 values of 0.99µM against MDA-231 cancer cell lines. Compound (Z)-6-(2,4-
dimethoxy-6-(4-methoxystyryl)benzylidene)-dihydropyrimidine-2,4,5(3H)-trione (16c) had 
an IC50 value of 1.28µM against the MCF-7 cell line.  
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Scheme 5. Synthesis of resveratrol analogs 16a-i; reagents and conditions: (a) POCl3, DMF, 0 
oC, 69% yield; (b) barbituric acid or thiobarbituric acid, methanol, RT, 6 hrs, 95-96% yield; (c) 
five membered active methylene compound, NH4OAc, AcOH, MWI, 1-2 min, 94-97% yield; 
(d) isobarbituric acid, ethanol, reflux, 4 hrs, 90% yield. 
 
Entry 
Breast cancer cell lines
MCF-7 (IC50) MDA-231 (IC50) 
16a 11.8 5.57
16b >40 7.59
16c 1.28 12.3
16d 7.93 4.24
16e 14.8 0.99
16f 2.40 10.3
16g 3.96 10.1
16h 1.99 4.09
Table 7. IC50 values (µM) for resveratrol analogs 16a-h. 
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The resveratrol analog, (E)-5-(2,4-dimethoxy-6-(4-methoxystyryl)benzylidene)-2-
iminothiazolidin-4-one (16i) was also evaluated for its in vitro cytotoxicity against a panel of 
human MCF-7, MDA-MB-231/ATCC, HS-578T, BT-549, T-47D, breast cancer cell lines 
(Table 8). This compound showed growth inhibition (GI50 values ranging from 1.4µM-
3.9µM) and cytotoxicity (LC50 values ranging from 7.1µM-65.7µM) amongst four out of five 
of the breast cancer cell lines utilized. 
 
Breast Cancer Panel/cell line GI50 LC50 
MCF7 1.44 7.89 
MDA-MB-231/ATCC 2.76 65.7 
HS 578T 2.55 >100 
BT-549 3.91 49.8 
T-47D 1.66 7.26 
MDA-MB-468 1.66 7.10 
aGI50: 50% Growth inhibition, concentration of drug resulting in a 50% reduction in net protein increase 
compared with control cells. bLC50: Lethal concentration, concentration of drug lethal to 50% of cells 
Table 8. Growth inhibition (GI50/ µM)a and cytotoxicity (LC50/ µM)b data of (Z)-2-amino-5-
(2,4-dimethoxy-6-(4-methoxystyryl) benzylidene)thiazol-4(5H)-one (16i). 
3. Conclusion 
In conclusion, novel N-benzyl aplysinopsin, combretastatin and resveratrol analogs have 
been synthesized and evaluated for their anticancer activity against a number of breast cell 
lines. In the N-benzyl aplysinopsin series, the analog (Z)-methyl-1-(4-cyanobenzyl)-3-((2,5-
dioxoimidazolidin-4-ylidene)methyl)-1H-indole-6-carboxylate (3n) emerged as promising 
lead compound for further structural optimization studies. The novel combretastatin 
analogs, (Z)-3-(benzo[b]thiophen-3-yl)-2-(3,4-dimethoxyphenyl)acrylonitrile (11b), and (Z)-
3-(benzo[b]thiophen-3-yl)-2-(3,4,5-trimethoxy phenyl)acrylonitrile (11c) were shown to be 
potent cytotoxic agents against breast cancer cell lines in culture and worthy of further 
evaluation in animal models of breast cancer. From the library of novel resveratrol analogs, 
the creatinine analog, (Z)-5-(2, 4-dimethoxy-6-(4-methoxystyryl)benzylidene)-2-imino-1-
methylimidazolidin-4-one (16e) was considered as a lead analog for subsequent structural 
optimization as a potential agent for the treatment of breast cancer.  
4. References 
Baur, J. A.; Sinclair, D. A. (2006), Nat. Rev. Drug Discov. 5(6), 493-506. 
Brew, C. T.; Aronchik, I.; Kosco, K.; McCammon, J.; Bjeldanes, L. F.; Firestone, G. L. (2009), 
Int J.Cancer. 124(10), 2294-302. 
Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A. K.; Lin, C. M.; Hamel, E. (1991), 
J. Med. Chem., 34, 2579. 
Dobroslawa Bialonska.; Jordan K. Zjawiony (2009), Marine Drugs, 7, 166-183. 
Hollenbeak, K. H;. Schmitz, F (1997). J. Lloydia, 40, 479.  
Jacobs, T. L.; Winstein, S.; Linden, G. B.; Robson, J. H.; Levy, E. F.; Seymour, D. (1948), 
Organic Synthesis, 28, 70-72. 
www.intechopen.com
 
Breast Cancer – Current and Alternative Therapeutic Modalities 
 
294 
Jang, M.; Cai, L.; Udeani, G. O.; Slowing, K. V.; Thomas, C. F.; Beecher, C. W.; Fong, H. H.; 
Farnsworth, N. R.; Kinghorn, A. D.; Mehta, R. G.; Moon, R. C.; Pezzuto, J. M (1997). 
Science, 275, 218. 
Kazlauskas, R.; Murphy, P. T.; Quinn, Wells, R. J (1997), Tetrahedron letters, 18, 61-64. 
Kondo, K.; Nishi, J.; Ishibashi, M.; Kobayashi, J (1994), J. Nat. Prod. 57, 1008-1011. 
Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.;Schmidt, J. M.; Pettit, G. R.; Hamel, E. 
(1988), Mol. Pharmacol. 34, 200. 
Madadi, N. R.; Reddy, Y. R.; Reddy, N. R.; Parkin, S.; Crooks, P. A (2010), Acta 
Crystallography , Section E. E66(7), o1792. 
McGown, A. T.; Fox, B. W. (1990), Cancer Chemother. Pharmacol. 26, 79. 
Macpherson, L. J.; Dubin, A. E.; Evans, M. J.; Marr, F.; Schultz, P. G.; Cravatt, B. F.; 
Patapoutian, A. (2007), Nature (London, United Kingdom), 445(7127), 541-545.  
Narsimha Reddy, Penthala.; Thirupathi Reddy, Yerramreddy.; Peter A. Crooks (2010). 
Bio.org & Med Chem Lett, 20(2), 591-593. 
Narsimha Reddy, Penthala.; Thirupathi Reddy, Yerramreddy.; Nikhil Reddy, Madadi.; Peter 
A. Crooks (2010), Bio.org & Med Chem Lett, 20, (15), 4468-4471. 
Narsimha Reddy, Penthala.; Thirupathi Reddy, Yerramreddy.; Peter A. Crooks (2011), 
Bio.org & Med Chem Lett, 21(5), 1411-1413. 
Narsimha Reddy, P.; Thirupathi Reddy, Y.; Parkin, S.; Crooks, P. A (2009), Acta 
Crystallographica, E65(11), o2909-o2910. 
Narsimha Reddy, P.; Thirupathi Reddy, Y.; Parkin, S.; Crooks, P. A (2009), Acta 
Crystallographica, E65(10), o2439-o2440.  
Narsimha Reddy, P.; Thirupathi Reddy, Y.; Parkin, S.; Crooks, P. A (2009), Acta 
Crystallographica, E65(3), o552. 
Ragaz, J (2009), Breast Cancer Res., 11, Suppl 3: S14. 
Shindikar, A. V.; Khan, F.; Viswanathan, C. L. (2006), Euro. J. Med. Chem., 41(6), 786-792.  
Thirupathi Reddy, Y.; Narsimha Reddy, P.; Srinivas, K.; Chendil Damodaran.; Peter A. 
Crooks (2010). Bio.org & Med. Chem., 18, (10), 3570-3574. 
Xian, F. H.; Ban, F. R.; Xiao, T. W.; Chen, X.; Hui, M. G.; Hai, L. Z.; Ren, X. T (2007). Euro. J. 
Med. Chem. 42, 263-267. 
www.intechopen.com
Breast Cancer - Current and Alternative Therapeutic Modalities
Edited by Prof. Esra Gunduz
ISBN 978-953-307-776-5
Hard cover, 540 pages
Publisher InTech
Published online 09, November, 2011
Published in print edition November, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Cancer is the leading cause of death in most countries and its consequences result in huge economic, social
and psychological burden. Breast cancer is the most frequently diagnosed cancer type and the leading cause
of cancer death among females. In this book, we discussed various therapeutic modalities from signaling
pathways through various anti-tumor compounds as well as herbal medicine for this deadly cancer. We hope
that this book will contribute to the development of novel diagnostic as well as therapeutic approaches.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Narsimha Reddy Penthala, Thirupathi Reddy Yerramreddy, Nikhil Reddy Madadi, Vijayakumar Sonar and
Peter A. Crooks (2011). Synthesis and In Vitro Screening of Novel Heterocyclic Compounds as Potential
Breast Cancer Agents, Breast Cancer - Current and Alternative Therapeutic Modalities, Prof. Esra Gunduz
(Ed.), ISBN: 978-953-307-776-5, InTech, Available from: http://www.intechopen.com/books/breast-cancer-
current-and-alternative-therapeutic-modalities/synthesis-and-in-vitro-screening-of-novel-heterocyclic-
compounds-as-potential-breast-cancer-agents
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
